F-star Therapeutics, Inc. (FSTX)

NASDAQ: FSTX · IEX Real-Time Price · USD
6.39
+0.03 (0.47%)
Jun 24, 2022 4:00 PM EDT - Market closed

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 20212020201920182017201620152014
Revenue
21.1711.2628.32000.350.950.74
Revenue Growth (YoY)
88.05%-60.26%----62.79%28.18%-
Gross Profit
21.1711.2628.32000.350.950.74
Selling, General & Admin
23.1319.5115.288.728.185.7452.41
Research & Development
28.7514.1331.3919.7513.0814.027.546.13
Other Operating Expenses
004.1500000
Operating Expenses
51.8833.6450.8228.4721.2519.7612.548.54
Operating Income
-30.71-22.39-22.5-28.47-21.25-19.4-11.6-7.81
Interest Expense / Income
0.841000001.91
Other Expense / Income
0.12.231.25-5.626.43-2.04-0.03-0
Pretax Income
-31.66-25.62-23.75-22.85-27.68-17.37-11.56-9.71
Income Tax
-0.37-0-0.7400000
Net Income
-31.28-25.62-23.01-22.85-27.68-17.37-11.56-9.71
Net Income Common
-31.28-25.62-23.01-22.85-27.68-17.37-11.56-9.71
Shares Outstanding (Basic)
173243211
Shares Outstanding (Diluted)
173243211
Shares Change
529.83%71.06%-57.72%31.07%53.70%27.69%82.24%-
EPS (Basic)
-1.88-9.69-14.89-6.36-9.92-9.56-8.12-12.44
EPS (Diluted)
-1.88-9.69-14.89-7.52-9.92-9.56-8.12-12.44
Free Cash Flow Per Share
-1.68-6.14-14.31-7.58-6.46-8.84-6.05-9.53
Gross Margin
100.00%100.00%100.00%--100.00%100.00%100.00%
Operating Margin
-145.10%-198.87%-79.44%---5512.50%-1225.79%-1057.72%
Profit Margin
-147.79%-227.60%-81.26%---4933.52%-1222.41%-1315.99%
Free Cash Flow Margin
-131.86%-144.15%-78.07%---4554.55%-909.09%-1007.05%
Effective Tax Rate
1.18%0.00%3.10%0.00%0.00%0.00%0.00%0.00%
EBITDA
-30.17-23.48-22.91-22.57-27.52-17.25-11.48-7.76
EBITDA Margin
-142.53%-208.56%-80.88%---4900.00%-1213.11%-1051.90%
Depreciation & Amortization
0.641.140.840.290.160.120.090.04
EBIT
-30.81-24.62-23.75-22.85-27.68-17.37-11.56-7.81
EBIT Margin
-145.56%-218.72%-83.86%---4933.52%-1222.41%-1057.59%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).